|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cardioprotection of cariporide evaluated by plasma myoglobin and troponin I in myocardial infarction in pigs显示文摘 | Letienne R Bel L Bessac AM | 2006 | Fundam Clin Pharmacol2006，20，2： | 1 |
| 2 | Effect of aliroeumab, a monoclonal antibody to PCSK9, on long-term cardiovascular out- comes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 3 | Effect of a1irocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 4 | Effectof alirocumab, a monoclonal antibody to PCSK9, on long-termcardiovascular outcomes following acute coronary syndromes:rationale and design of the ODYSSEY outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | AmHeart J2014，168，5： | 1 |
| 5 | Effect of alirocumab,a monoclonal antibody to PCSK9,on long-term cardiovascular outcomes following acute coronary syndromes:rationale and design of the ODYSSEY outcomes trial显示文摘 | SCHWARTZ GG BESSAC L BERDAN LG | 2014 | Am Heart J2014，168，5： | 1 |
| 6 | Effect of alirocumab, a monoelonal antibody to PCSK9, on long-term cardiovascular out- comes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial显示文摘 | Schwartz G G Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 7 | Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 8 | Cardioprotection of cariporide evaluated by plasma myoglobin and troponin Ⅰ in myocardial infarction in pigs显示文摘 | Bel L Bessac AM | 2006 | Fundam Clin Pharmacol2006，20，2： | 1 |
| 9 | Cardioprotection of cariporide evaluated by plasma myoglobin and troponin I in myocardial in farction in pigs显示文摘 | Letienne R Bel L Bessac AM | 2006 | Fundam Clin Pharmacol2006，20，2： | 1 |
| 10 | Cardioprotection of caripofide evaluated by plasma myoglobin and troponin I in myocardiainfarction in pigs显示文摘 | Letienne R Bel L Bessac A M | 2006 | Fundam Clin Pharmacol2006，20，2： | 1 |
| 11 | Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 12 | Effect of alirocum- ab,a monoclonal antibody to PCSK9 ,on long-term cardiovas- cular outcomes following acute coronary syndromes:rationale and design of the odyssey outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 13 | 致动脉粥样硬化脂质和主要心血管事件的关系显示文摘他汀类药物和依泽替米贝(ezetimibe)的临床结局试验中观察到低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)水平降低(低至54mg/dL,1mmol/L=0.026mg/dL)与主要不良心血管事件(major adverse cardiovascular events,MACE)之间的连续关系。然而,LDL-C〈50mg/dL人群中是否有存在上述联系尚不清楚。 | 刘莉 叶鹏 Ray KK Ginsberg HN Davidson MH Pordy R Bessac L Minini P Eckel RH Cannon CP | 2016 | 中华高血压杂志2016，24，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员